Mon, July 29, 2024
Fri, July 26, 2024
Thu, July 25, 2024

Charles Duncan Reiterated (AXSM) at Buy and Held Target at $107 on, Jul 26th, 2024


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. buy-and-held-target-at-107-on-jul-26th-2024.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Charles Duncan of Cantor Fitzgerald, Reiterated "Axsome Therapeutics, Inc." (AXSM) at Buy and Held Target at $107 on, Jul 26th, 2024.

Charles has made no other calls on AXSM in the last 4 months.



There are 9 other peers that have a rating on AXSM. Out of the 9 peers that are also analyzing AXSM, 1 agrees with Charles's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Jason Gerberry of "B of A Securities" Maintained at Hold with Decreased Target to $95 on, Thursday, July 18th, 2024


These are the ratings of the 8 analyists that currently disagree with Charles


  • Ami Fadia of "Needham" Initiated at Strong Buy and Held Target at $130 on, Monday, July 22nd, 2024
  • Leonid Timashev of "RBC Capital" Reiterated at Buy and Held Target at $131 on, Monday, July 22nd, 2024
  • Graig Suvannavejh of "Mizuho" Reiterated at Strong Buy and Held Target at $106 on, Wednesday, June 12th, 2024
  • Raghuram Selvaraju of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $190 on, Thursday, June 6th, 2024
  • Joel Beatty of "Baird" Maintained at Buy with Increased Target to $112 on, Tuesday, May 7th, 2024
  • David Hoang of "Citigroup" Maintained at Strong Buy with Decreased Target to $125 on, Tuesday, May 7th, 2024
  • Vikram Purohit of "Morgan Stanley" Upgraded from Hold to Buy and Increased Target to $115 on, Monday, April 29th, 2024
  • Joon Lee of "Truist Securities" Maintained at Strong Buy and Held Target at $150 on, Tuesday, March 26th, 2024

Publication Contributing Sources